Related Experiment Video
Updated: Jul 13, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Predictors of pharmacoresistant epilepsy
Nikolas Hitiris1, Rajiv Mohanraj, John Norrie
1Epilepsy Unit, Division of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow G11 6NT, Scotland, UK.
Epilepsy Research
|July 14, 2007
Summary
More pre-treatment seizures and psychiatric conditions like depression predict drug-resistant epilepsy. These factors, along with family history and brain injury, indicate a higher likelihood of refractory epilepsy, impacting treatment outcomes.
Area of Science:
- Neurology
- Clinical Medicine
- Epilepsy Research
Background:
- Epilepsy affects millions globally, with a significant subset experiencing pharmacoresistance.
- Understanding predictors of refractory epilepsy is crucial for optimizing patient care and treatment strategies.
Purpose of the Study:
- To identify clinical factors predicting pharmacoresistance in newly diagnosed epilepsy patients.
- To investigate the association between psychiatric comorbidity and antiepileptic drug response.
Main Methods:
- Analysis of outcome data from 780 epilepsy patients followed for 20 years.
- Logistic regression models (univariate and multivariate) to assess predictors of pharmacoresistance.
- Classification of patients into seizure-controlled and refractory epilepsy groups.
Main Results:
- Higher numbers of pre-treatment seizures (>10) doubled the risk of refractory epilepsy.
- Pharmacoresistance associated with family history, febrile seizures, traumatic brain injury, drug use, and psychiatric comorbidity (especially depression).
- Gender, neurological deficit, and mental retardation did not predict poorer outcomes.
Conclusions:
- Psychiatric comorbidity, particularly depression, is a significant, novel predictor of poor response to antiepileptic drugs.
- Interactions between neurobiological processes of psychiatric disorders and epilepsy may increase brain dysfunction and pharmacoresistance.
- Early identification of these factors can guide personalized epilepsy management.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...